MoonLake Immunotherapeutics (MLTX) Expected to Announce Quarterly Earnings on Tuesday

MoonLake Immunotherapeutics (NASDAQ:MLTX) is projected to release its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect MoonLake Immunotherapeutics to post earnings of ($0.9178) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 12:30 PM ET.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its earnings results on Monday, May 11th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.07). On average, analysts expect MoonLake Immunotherapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

MoonLake Immunotherapeutics Stock Down 2.9%

Shares of MoonLake Immunotherapeutics stock opened at $18.44 on Friday. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -4.76 and a beta of 1.04. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The company has a current ratio of 8.60, a quick ratio of 8.60 and a debt-to-equity ratio of 0.39. The business’s 50 day simple moving average is $19.12 and its 200-day simple moving average is $17.85.

Insider Buying and Selling at MoonLake Immunotherapeutics

In related news, insider Kristian Reich sold 50,000 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $19.43, for a total value of $971,500.00. Following the completion of the sale, the insider owned 2,824,551 shares of the company’s stock, valued at $54,881,025.93. This represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Da Silva Jorge Santos sold 68,289 shares of the company’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the completion of the sale, the chief executive officer directly owned 2,774,893 shares of the company’s stock, valued at $55,553,357.86. The trade was a 2.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 344,800 shares of company stock valued at $6,820,071. Company insiders own 10.40% of the company’s stock.

Institutional Trading of MoonLake Immunotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in MLTX. Geode Capital Management LLC boosted its holdings in shares of MoonLake Immunotherapeutics by 0.9% in the second quarter. Geode Capital Management LLC now owns 59,553 shares of the company’s stock valued at $2,809,000 after acquiring an additional 559 shares in the last quarter. Squarepoint Ops LLC raised its holdings in MoonLake Immunotherapeutics by 3.7% during the second quarter. Squarepoint Ops LLC now owns 17,571 shares of the company’s stock worth $829,000 after purchasing an additional 629 shares in the last quarter. Russell Investments Group Ltd. lifted its position in MoonLake Immunotherapeutics by 45.4% in the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after purchasing an additional 1,069 shares during the period. BNP Paribas Financial Markets lifted its position in MoonLake Immunotherapeutics by 18.9% in the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock worth $52,000 after purchasing an additional 1,158 shares during the period. Finally, Legal & General Group Plc lifted its position in MoonLake Immunotherapeutics by 7.3% in the second quarter. Legal & General Group Plc now owns 20,905 shares of the company’s stock worth $987,000 after purchasing an additional 1,425 shares during the period. 93.85% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on MLTX shares. Needham & Company LLC increased their target price on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of MoonLake Immunotherapeutics in a research report on Monday, July 20th. Leerink Partners increased their price objective on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the stock an “outperform” rating in a report on Wednesday, July 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 12th. Finally, BTIG Research reissued a “buy” rating and set a $30.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 9th. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics presently has an average rating of “Hold” and a consensus target price of $24.21.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.